Sign in Create account

Medicamen Biotech Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MEDICAMEQ BSE: 531146
₹321.75
▼ -0.25 (-0.08%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
53/100
Moderate
Valuation
29/100
Expensive
Momentum
37/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹436 Cr
PE (TTM)
42.4
Industry median 36.1 (152 companies)
Price to Book
1.6
PEG (TTM)
4.0
Institutions holding %
0.47%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
25.7
Relative return vs Sector, qtr %
22.5
Free Cash Flow
₹-38 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
53.72%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-2.98%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
24.13%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
2.81%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
14.05%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.54
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.17
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
5.42
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
5.76%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
8.89%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.41%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
2.63%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
5.45%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
3.56%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.17)
  • No Return on equity is 15% or more (3.6%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.1%
Low 310.1000 · High 329.8500
1W return
0.6%
Low 292.4000 · High 330.3000
1M return
23.1%
Low 258.0000 · High 363.9000
52W return
6.9%
Low 212.4000 · High 447.6500
Lifetime High ₹1201.4000 (Sept. 1, 2022)
Lifetime Low ₹219.8800 (Aug. 17, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
321.0
10D
318.5
20D
306.8
50D
281.8
100D
275.9
200D
288.2

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
48.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

320.57
Pivot
First resistance331.03
Second resistance340.32
Third resistance350.78
First support311.28
Second support300.82
Third support291.53
Day RSI60.8
Day MFI85.1
Day MACD16.74
Day MACD signal18.63

Beta

1M-0.03
3M0.00
1Y0.86
3Y1.15

Price change analysis

↑ 23.1%
Over 1 Month
LowHigh
258.00363.90
↑ 22.5%
Over 3 Months
LowHigh
215.00363.90
↑ 38.9%
Over 6 Months
LowHigh
212.40363.90
↑ 6.9%
Over 1 Year
LowHigh
212.40447.65
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 42.4 (own history: 32.2–69.3)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹44 Cr
Net profit (June 30, 2026)
₹3 Cr
Basic EPS (June 30, 2026)
₹1.8600

Ranks #106 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter40.46%
  • FII/FPI0.07%
  • Public59.07%

Largest holders

NameCategoryShares %Shares
Shivalik Rasayan LimitedPromoter40.4600%5487095
Pharmadanica A/SPublic9.8800%1340000
Veralogix Holdings(Pty) LtdPublic4.4200%599995
Ginnerup Capital ApsPublic2.6200%354820
Investor Education and Protection Fund (IEPF)Public1.2600%170861

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 40.46% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.10% to 0.07% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 30 insider trades, 1 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
24 Sep 2025 Sanjay Bansal Director Sell 0 ₹0
17 Dec 2024 Geetika Madan Immediate relative Sell 0 ₹0
17 Dec 2024 Geetika Madan Immediate relative Sell 0 ₹0
17 Dec 2024 Geetika Madan Immediate relative Sell 0 ₹0
18 Sep 2024 Geetika Madan Other Sell 0 ₹0
18 Sep 2024 Geetika Madan Other Sell 0 ₹0
18 Sep 2024 Geetika Madan Other Sell 0 ₹0
18 Sep 2024 Geetika Madan Other Sell 0 ₹0
26 Mar 2024 Geetika Madan Other Sell 0 ₹0
23 Mar 2024 Shivalik Rasayan limited Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 46 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
22 Mar 2024 SHIVALIK RASAYAN LIMITED Bulk Buy 200,000 421.8600 NSE
22 Mar 2024 GROWEL REMEDIES LIMITED Bulk Sell 200,000 421.8600 NSE
16 Nov 2016 JMP SECURITIES PVT LTD Bulk Sell 53,811 252.1100 BSE
16 Nov 2016 JMP SECURITIES PVT LTD Bulk Buy 55,011 250.9600 BSE
1 Mar 2016 MEDICAMEN CANADA INC Bulk Sell 140,000 44.0800 BSE
7 Jan 2016 BP FINTRADE PRIVATE LIMITED Bulk Buy 22,012 77.3000 BSE
7 Jan 2016 VISIONSTAR Bulk Buy 50,000 76.5100 BSE
7 Jan 2016 BP FINTRADE PRIVATE LIMITED Bulk Sell 52,306 76.8300 BSE
16 Nov 2015 RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED Bulk Buy 48,498 35.7000 BSE
16 Nov 2015 GEOMETRIC SECURITIES & ADVISORY P LTD Bulk Sell 51,190 35.7000 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹1.00 per share
Dividend yield 0.31%
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 1.0000 — —
18 Sep 2026 Dividend - Re 1 Per Share 1.0000 19 Sep 2026
19 Sep 2025 Dividend - Re 1 Per Share 1.0000 19 Sep 2025
19 Sep 2024 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —
20 Sep 2023 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —
19 Sep 2022 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
27 May 2026 Financial Results/Dividend Yes
13 Feb 2026 Financial Results Yes
14 Nov 2025 Financial Results Yes
12 Aug 2025 Financial Results Yes

Corporate Announcements

All 269 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Trading Plan under PIT Medicamen Biotech Limited has informed the Exchange regarding Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
30 Sep 2026 Company Update Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015
28 Sep 2026 Insider Trading / SAST Medicamen Biotech Ltd-$ - 531146 - Closure of Trading Window
28 Sep 2026 Trading Window Medicamen Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
28 Sep 2026 Company Update Medicamen Biotech Ltd-$ - 531146 - Voting Reults Of 33Rd Annual General Meeting - September 26, 2026
26 Sep 2026 Shareholders meeting Outcome/ Summary of proceedings of the 33rd Annual General Meeting of Medicamen Biotech Limited held on 26/09/2026
5 Sep 2026 Company Update Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Sep 2026 Copy of Newspaper Publication Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
3 Sep 2026 Updates Medicamen Biotech Limited has informed the Exchange regarding 'Submission of Integrated Annual Report for FY 2025-26 and Notice of the 33rd Annual General Meeting ( AGM ) of Medicamen Biotech Limited ( the Company ) to be held through Video Conferencing/Other Audio-Visual Means ( VC/OAVM ) on September 26, 2026 '.
3 Sep 2026 Updates Medicamen Biotech Limited has informed the Exchange regarding 'Submission of Business Responsibility and Sustainability Report for the financial year 2025-26'.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.17)
  • Healthy liquidity (Current Ratio 2.54)

Weaknesses

  • Low Return on Equity (3.6%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (42.4) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Medicamen Biotech Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.